Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Mendus AB (publ)
IMMUCurrent price
9.7 SEK
+0.5 SEK (+5.39%)
Last closed
9.5 SEK
Company
www.mendus.com
ISIN
SE0005003654
Sector
Healthcare
Industry
Biotechnology
Exchange
Stockholm Exchange
Capitalization
497 373 420 SEK
Yield for 12 month
-23.02 %
1Y
3Y
5Y
10Y
15Y
IMMU
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company has a collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden. Address: VAestra TrAedgArdsgatan 15, Stockholm, Sweden, 111 53
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
274.61 SEKP/E ratio
–Dividend Yield
–Current Year
+28 862 342 SEK
Last Year
+3 034 464 SEK
Current Quarter
+633 238 SEK
Last Quarter
+2 820 686 SEK
Current Year
+22 476 296 SEK
Last Year
-1 877 415 SEK
Current Quarter
-1 023 303 SEK
Last Quarter
+1 180 347 SEK
Key Figures IMMU
1 year
3 years
5 years
10 years
EBITDA
-116 576 253 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-9.31 %
PEG Ratio
–
Return On Equity TTM
-19.35 %
Wall Street Target Price
274.61 SEK
Revenue TTM
32 900 856 SEK
Book Value
13.67 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
4707.7 %
Dividend Yield
–
Gross Profit TTM
3 034 461 SEK
Earnings per share
-5.89 SEK
Diluted Eps TTM
-5.89 SEK
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics IMMU
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMMU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:20
Payout Ratio
–
Last Split Date
03.06.2024
Dividend Date
–
Stock Valuation IMMU
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
338.4453
Price Sales TTM
15.1173
Enterprise Value EBITDA
-2.6339
Price Book MRQ
0.7211
Financials IMMU
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators IMMU
For 52 weeks
7.19 SEK
16.6 SEK
50 Day MA
8.8 SEK
Shares Short Prior Month
–
200 Day MA
9.07 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart